

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Please complete the **ABSTRACT TEMPLATE** online, for Biomed 2025 Company Presentations

All items marked with an * are mandatory to complete

The maximum number of words for this abstract is 400

Please be sure to complete the following:

Company name immunai * Website-----www.immunai.com--- *

CEO name-----Noam Solomon---*

Select a **CATEGORY**: Digital *

(Delete categories you are not selecting)

Select up to two **SESSIONS** per abstract from the list below *

(Delete sessions you are not selecting)

- Agentic AI; Solutions in medical applications, transformative opportunities in healthcare
- AI Meets Pharma: Building a Sustainable Value for Biotech AI innovation in Drug Development

You may delete the section instructions, leaving only the bolded bullet title

Answers below should not exceed 60 words per question:

Executive summary

- Immunai is building a platform for derisking development decisions for immunomodulatory therapeutics. Immunai's platform deciphers the immune effect in health and diseases using unique immune multi-omic single-cell data foundation, advanced analytics and cutting-edge experimental immunology. Immunai's platform is applicable to most diseases, with a focus on cancer and autoimmunity.

Business Strategy

- Immunai collaborates with leading biopharmaceutical companies and academic research institutions to derisk drug development decisions, focusing on clinical trial optimization and patient stratification. We work with over 30 partners including 5 of the top 15 pharma companies

Core Technology

- Immunai's offerings rely on its Immunodynamics Engine (IDE™), an AI-based framework for deriving immune insights and recommendations, coupled with AMICA - the world's largest cell-level clinical immune database. AMICA drives drug development recommendations and facilitates transfer learning of insights, which are then validated through advanced molecular assays. This vertical integration of capabilities allows us to generate novel, differentiated insights for discovery and development.

Product Profile/Pipeline

- We have > 30 partnerships with academic institutions and biopharma, for discovering and advancing novel therapeutics, including 5 of the top 15 pharma companies. We have built proprietary knowledge libraries and deep expertise in a variety of immune cell compartments, including T-cell and myeloid suppression. Our long-term vision is pan-immune, but we're focusing first on immuno-oncology and autoimmune diseases.

What's Next?

- Immunai's next key milestone is to co-develop preclinical candidates together with biotechnology and biopharma companies. Immunai has focused its platform on supporting clinical decision-making, including dose justification and patient stratification.

